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Highlights
• We develop novel glucose-insulin systems modeling rates of glucose in-
fusions and insulin injections.
• The periodic solution for type 1 and permanence for type 2 diabetes of
the system have been studied.
• The results showed that the period, the frequency and the dose of
glucose infusions and insulin injections are crucial.
• The blood concentration can be controlled within a normal range using
the proposed models.
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Abstract
Novel mathematical models with open and closed-loop control for type
1 or type 2 diabetes mellitus were developed to improve understanding of
the glucose-insulin regulatory system. A hybrid impulsive glucose-insulin
model with different frequencies of glucose infusions and insulin injections
was analyzed, and the existence and uniqueness of the positive periodic solu-
tion for type 1 diabetes, which is globally asymptotically stable, was studied
analytically. Moreover, permanence of the system for type 2 diabetes was
demonstrated which showed that the glucose concentration level is uniformly
bounded above and below. To investigate how to prevent hyperinsulinemia
and hyperglycaemia being caused by this system, we developed a model in-
volving periodic intakes of glucose with insulin injections applied only when
the blood glucose level reached a given critical glucose threshold. In addition,
our numerical analysis revealed that the period, the frequency and the dose of
glucose infusions and insulin injections are crucial for insulin therapies, and
the results provide clinical strategies for insulin-administration practices.
Keywords:
Diabetes, Glucose-insulin system, Glucose infusion, Insulin injection,
Critical glucose threshold
Preprint submitted to Communications in Nonlinear Science and Numerical SimulationFebruary 8, 2016
ACCEPTED MANUSCRIPT
A
C
C
E
P
T
E
D
 M
A
N
U
S
C
R
IP
T
1. Introduction
Diabetes mellitus is an epidemic disease worldwide, characterized by
plasma glucose concentrations mostly remaining above the normal range
as a consequence of the absolute or relative lack of insulin. Depending on
the pathogenic mechanisms involved, diabetes mellitus is divided into three
types: type 1 diabetes, type 2 diabetes and gestational diabetes. Type 1 dia-
betes is generally due to the immune system of the patients destroying β cells
in the islets of Langerhans of the pancreas and thus preventing production
and secretion of insulin. In type 2 diabetes, either the β-cells do not produce
enough insulin or the so-called insulin resistance occurs when the system be-
comes dysfunctional and prevents cells from taking up glucose efficiently [1].
Gestational diabetes refers to cases when pregnant women who have never
had diabetes develop high plasma glucose levels during pregnancy. Since the
discovery of diabetes, the main aims of researchers have been to find out how
the endocrine metabolic system works [2, 3], the reasons for dysfunctions
[4] and effective and efficient therapies improving the daily life of diabetic
patients.
A typical therapy is subcutaneous injection of insulin or its analogues by
using an insulin pump. This not only provides a basic treatment for type 1
diabetes [5], but also supplies a viable alternative for type 2 diabetes although
the latter can be controlled, or even cured, by life-style changes such as di-
etary adjustment, physical exercise, stopping smoking and avoiding exposure
to second-hand smoke [6-8]. A drawback of insulin therapy, however, is the
difficulty in the monitoring of plasma glucose concentrations non-invasively.
Thus, all current therapies are followed by the so-called open-loop approach
in which glucose concentrations are not measured automatically. When an
accurate non-invasive glucose monitoring technique is developed, the open-
loop treatment can be replaced by closed-loop therapy, with an ”artificial
pancreas” delivering insulin automatically according to variations in blood
glucose levels [9-11].
However, the need for reliable predictive models and the lack of effective
and efficient control algorithms are two major impediments in the develop-
ment of the artificial pancreas [12]. To conquer these issues, several reliable
mathematical models which can determine the time and the dose of insulin
injections for control algorithms have been proposed and investigated [13-15].
Such models reflect the interaction mechanisms between glucose and insulin
in a kinetic system. Meanwhile, periodic insulin administration has been
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employed to mimic impulsive injections for type 1 or type 2 diabetes mellitus
treatment regimes [14, 15]. Inspired by Wang et al. [14, 15], Huang et al.
[12] formed a new model which takes impulsive insulin injection into account
either periodically or by monitoring the plasma glucose concentration level.
The model can be described by:


dG(t)
dt
= Gin − σ2G(t)− a
(
c+
kI(t)
l + I(t)
)
G(t) + b,
dI(t)
dt
=
σ1G
2(t)
α21 +G
2(t)
− dI(t),


t 6= hτ,
G(t+) = G(t),
I(t+) = I(t) + σ,
}
t = hτ,
(1.1)
where G(t) is the glucose concentration at time t, I(t) is the insulin con-
centration at time t, Gin is the estimated average constant rate of glucose
input, σ2 indicates the insulin-independent glucose uptake rate, the term
aG(t)(c + mI(t)/(n + I(t))) stands for the insulin-dependent glucose uti-
lization, b represents the hepatic glucose production, σ1G
2(t)/(α21 + G
2(t))
is insulin secretion stimulated by elevated glucose concentration caused by
complex pathways including chemical-electrical processes, d indicates the in-
sulin degradation rate. Furthermore, all parameters are positive [12] and the
initial conditions are G(0) = G0 > 0, I(0) = I0 > 0. τ is the period of the
impulsive injection, σ denotes the dose of insulin in each injection and is
injected as an impulse at discrete times t = hτ, h ∈ Z+ = {1, 2, 3, ...}.
Although the authors obtained many meaningful results theoretically [12],
for the sake of simplicity, they assumed that the constant glucose exogenous
infusion rate Gin is described by a continuous process in a period. However,
this can not reflect reality very well because constant glucose exogenous in-
fusion is usually a discrete process with an impulse at discrete times [2], for
example, uptake from food (i.e., from breakfast, lunch and dinner) or the
rate of intravenous glucose infusion at intervals [3], although this might be
provided continuously in a hospital context. Therefore, in order to better re-
flect reality and model the treatment currently available for clinical use, we
consider that glucose infusion is applied only at each impulsive point τn, and
at each impulsive point λm there is an impulsive injection of insulin. These
modifications result in the following model based on the two impulsive point
series [16, 17]:
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

dG(t)
dt
= −σ2G(t)− a
(
c+
kI(t)
l + I(t)
)
G(t) + b,
dI(t)
dt
=
σ1G
2(t)
α21 +G
2(t)
− dI(t),


t 6= τn, t 6= λm,
G(τ+n ) = G(τn) +Gin,
I(τ+n ) = I(τn),
}
t = τn,
G(λ+m) = G(λm),
I(λ+m) = I(λm) + σ,
}
t = λm,
(1.2)
where τn(n = 1, 2, ...) and λm(m = 1, 2, ...) are impulsive point series at
which glucose infusion and insulin injection are applied, respectively. It is
thus possible to rank the different patterns of glucose infusion in terms of their
dynamic effects in relation to the timing of insulin injection. Furthermore,
it has been revealed that the oscillatory insulin delivery with a periodicity
is more efficient in reducing plasma glucose concentration level [15, 18], and
the main characteristic of system (1.2) is in agreement with how the insulin
pump works in an open-loop fashion.
Although the insulin pumps with open-loop approach have made major
contributions to clinical practice, open-loop therapy changes the life styles
of the patients and increases their likelihoods of becoming hyperinsulinemic
or hyperglycaemic. Therefore, from a theoretical point of view, the most
effective insulin therapy for patients is to control their glucose levels within
a desirable range, once the blood glucose reaches a critical glucose threshold
(CGT) instead of periodic injections of insulin, as shown in Fig. 1. The
critical glucose threshold can be defined as the glucose level in the blood
when insulin injections must be taken to prevent the dangerous glucose level
(DGL) from being reached and exceeded, where the DGL is the blood glucose
level that will cause harm to patients. For example, insulin injections must
be taken once the critical concentration of glucose is observed by a glucose
monitoring system so that the DGL can not be exceeded, that is, sufficient
lead time is needed between the time when the critical concentration of glu-
cose is observed and the time when a treatment is applied (Obviously, CGT
is less than DGL). Thus the most reasonable treatment is that insulin is
injected automatically in a closed-loop technique integrated with the glu-
cose monitoring system. Based on system (1.2), we propose a novel hybrid
5
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impulsive model with threshold:

dG(t)
dt
= −σ2G(t)− a
(
c+
kI(t)
l + I(t)
)
G(t) + b, t 6= τn,
dI(t)
dt
=
σ1G
2(t)
α21 +G
2(t)
− dI(t), G < GC or I > IC ,
G(τ+n ) = G(τn) +Gin,
I(τ+n ) = I(τn),
}
t = τn,
G(λ+m) = G(λm),
I(λ+m) = I(λm) + σ,
}
G ≥ GC and I ≤ IC ,
(1.3)
where τn(n = 1, 2, ...) is an impulsive point series at which glucose infusion
works normally, and λm is the time series at which the glucose level reaches
the CGT and the injection of insulin should be applied. The initial condition
G(0) = G0 ≤ GC , I(0) = I0, GC is an adjustable constant threshold value
for the glucose level, IC is another adjustable constant threshold value for
the insulin level. When the blood glucose level reaches GC (CGT), then the
injection of insulin with dose of σ is performed and the glucose level must
decrease when the insulin level surpasses IC .
The paper is organized as follows: In section 2, we focus on system (1.2)
and investigate its dynamic behaviors. The existence and stability of the pos-
itive periodic solution is studied under different cases. Furthermore, by using
the comparison theorem, we have proved that the system (1.2) is permanent.
In addition, numerical simulations have confirmed our theoretical work and
insulin therapies for patients are also discussed. Moreover, in section (3),
system (1.3) is investigated numerically and the simulation results revealed
that the blood glucose level could be controlled very well within the normal
range. Finally, we discuss our results combined with insulin therapies, but
additional work is needed to provide reliable predictive models and efficient
control algorithms for developing the artificial pancreas.
2. Mathematical analysis of system (1.2) for open-loop technique
As mentioned before, for type 1 diabetes there is no insulin produced or
secreted, this case corresponds to σ1 = 0 in system (1.2) and (1.3). Now we
investigate the dynamics of system (1.2) for type 1 diabetes.
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2.1. Existence and stability of the periodic solution of system (1.2) for type
1 diabetes
There are two impulsive point series when glucose infusion and insulin
injection are applied. Therefore, it is possible to rank the different patterns
of glucose infusion in terms of their dynamic effects in relation to the timing
of insulin injection. We consider several different cases in terms of the timing
of controlling the blood glucose level from a practical point of view.
Case 1 Glucose infusions are more frequent than insulin injections.
Assume λm+1 − λm ≡ TN for all m(m ∈ N ), where TN is the period of
impulsive injections of insulin. For this case, the system (1.2) is said to be a
TN periodic system if there exists a positive integer kp such that
τn+kp = τn + TN .
where kp denotes the times of glucose infusions during the period TN . This
implies that in each period TN , kp times glucose infusions are applied.
When σ1 = 0, the variable G does not appear in the second equation of
system (1.2). Therefore, for the dynamics of insulin I(t) we only need to
consider the following subsystem:

dI(t)
dt
= −dI(t), t 6= τn, t 6= λm,
I(τ+n ) = I(τn), t = τn,
I(λ+m) = I(λm) + σ, t = λm,
(2.1)
Denote ∆i = τi+1 − τi, i = 0, 1, 2, ..., kp, where ∆0 = τ1,∆kp = TN − τkp .
It is shown in Appendix A that there exists a globally stable TN periodic
solution ITN (t) for system (2.1), substituting ITN (t) into the first equation
of (1.2) for I(t), we get a positive TN periodic solution with the complete
expression (ITN (t), GTN (t)) over the h−th time interval hTN < t ≤ (h+1)TN
of system (1.2) for type 1 diabetes. Now we prove that the positive periodic
solution (ITN (t), GTN (t)) is globally stable under Case 1.
Theorem 2.1 If σ1 = 0, then the positive TN periodic solution (I
TN (t), GTN (t))
of system (1.2) for type 1 diabetes is globally asymptotically stable.
Proof. The local stability of the periodic solution (ITN (t), GTN (t)) can
be determined by considering the behavior of small amplitude perturbations
(u(t), v(t)) of the solution. Define
G(t) = GTN (t) + u(t), I(t) = ITN (t) + v(t),
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then it follows that (
u(t)
v(t)
)
= Φ(t)
(
u(0)
v(0)
)
,
where Φ(t) satisfies
dΦ(t)
dt
=
(
−ξ − akI
TN (t)
l+ITN (t)
− akG
TN (t)
l+ITN (t)
0 − d
)
Φ(t),
with Φ(0) = I the identity matrix. The linearization of the resetting impul-
sive condition of (1.2) becomes(
u((h+ 1)T+N )
v((h+ 1)T+N )
)
=
(
1 0
0 1
) (
u((h+ 1)TN)
v((h+ 1)TN)
)
,
and (
u((hTN + τi)
+)
v((hTN + τi)
+)
)
=
(
1 0
0 1
) (
u(hTN + τi)
v(hTN + τi)
)
.
Then the stability of the periodic solution (ITN (t), GTN (t)) is determined by
the eigenvalues of
θ =
(
1 0
0 1
)
Φ(TN).
Therefore, all eigenvalues of θ are given by
η1 = exp
(∫ (h+1)TN
hTN
[
−ξ −
akITN (t)
l + ITN (t)
]
dt
)
=
kp∏
j=0
ηj, η2 = e
−dTN ,
where
ηj = exp


∫ τj+1+hTN
τj+hTN

−ξ −
akI∗exp[−d(
j−1∑
i=0
∆i + t− τj − hTN)]
l + I∗exp[−d(
j−1∑
i=0
∆i + t− τj − hTN)]

 dt

 ,
from the expression of ITN (t), when t ∈ (τj + hTN , τj+1 + hTN ], we get
ITN (t) = I∗exp[−d
j−1∑
i=0
∆i]exp[−d(t− τj − hTN)](j = 0 · · · kp),
8
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substitute it into ηj, by calculation,
ηj = exp(−ξ∆j)
σexp[−d
j∑
i=0
∆i] + 1− exp(−dTN)
σexp[−d
j−1∑
i=0
∆i] + 1− exp(−dTN)
,
it is obvious that ηj < 1. Besides, η2 < 1 always hold. According to Floquet
theory [19, 20], the positive TN periodic solution (I
TN (t), GTN (t)) is locally
asymptotically stable.
In the following, we prove that the periodic solution (ITN (t), GTN (t)) is
a global attractor. According to the proof of boundedness for the system
(2.1), we can get I(t)→ ITN (t) as t→∞. Choosing ε1 > 0 and ε2 > 0 small
enough such that (1 − ε1)I
TN (t) < I(t) < (1 + ε2)I
TN (t) for all t > t1 > 0.
From the first equation of system (1.2), we note that
dG(t)
dt
≥ b− (σ2 + ac)G(t)−
akG(t)(1 + ε2)I
TN (t)
l + (1 + ε2)ITN (t)
and
dG(t)
dt
≤ b− (σ2 + ac)G(t)−
akG(t)(1− ε1)I
TN (t)
l + (1− ε1)ITN (t)
.
then we obtained the following two impulsive equations

dG′(t)
dt
= b− (σ2 + ac)G
′(t)−
akG′(t)(1 + ε2)I
TN (t)
l + (1 + ε2)ITN (t)
, t 6= τn, t 6= λm,
G′(τ+n ) = G
′(τn) +Gin, t = τn,
G′(λ+m) = G
′(λm), t = λm,
(2.2)
and

dG′′(t)
dt
= b− (σ2 + ac)G
′′(t)−
akG′′(t)(1− ε1)I
TN (t)
l + (1− ε1)ITN (t)
, t 6= τn, t 6= λm,
G′′(τ+n ) = G
′′(τn) +Gin, t = τn,
G′′(λ+m) = G
′′(λm), t = λm.
(2.3)
According to the subsystem (A.2), we replace ITN (t) by (1 + ε2)I
TN (t) in
equation (A.6), which yields a unique globally asymptotically stable positive
9
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periodic solution G′TN (t) in interval (hTN , (h+ 1)TN ] for subsystem (2.2),
G′TN (t) =


G′1(t), t ∈ (hTN , τ1 + hTN ],
G′2(t), t ∈ (τ1 + hTN , τ2 + hTN ],
...
G′kp+1(t), t ∈ (τkp + hTN , (h+ 1)TN ].
Similarly, we get the expression of the periodic solutionG′′TN (t) for subsystem
(2.3),
G′′TN (t) =


G′′1(t), t ∈ (hTN , τ1 + hTN ],
G′′2(t), t ∈ (τ1 + hTN , τ2 + hTN ],
...
G′′kp+1(t), t ∈ (τkp + hTN , (h+ 1)TN ].
According to the Comparison theorem, for any ε > 0 small enough, there
exists a t2 > t1 such that
G′TN (t)− ε < G′(t) ≤ G(t) ≤ G′′(t) < G′′TN (t) + ε
for all t > t2. Let ε, ε1, ε2 → 0, then G
′TN (t) → GTN (t) and G′′TN (t) →
GTN (t), which leads to
GTN (t)− ε < G(t) < GTN (t) + ε
for all t > t2, that is G(t) → G
TN (t) as t → ∞. It follows that the periodic
solution (ITN (t), GTN (t)) is a global attractor, and consequently the global
stability follows. This completes the proof.
Case 2 Insulin injections are more frequent than glucose infusions.
Assume τn+1−τn ≡ Tp for all n(n ∈ N ), where Tp is the period of glucose
infusions. For this case, system (1.2) is said to be a Tp periodic system if
there exists a positive integer kN such that
λm+kN = λm + Tp.
This implies that in each period Tp, kN times insulin injections are applied.
For this case, there are kN times insulin injections during the period Tp.
Similarly, denote ∆i = λi+1 − λi, i = 0, 1, 2, ..., kN , where ∆0 = λ1,∆kN =
Tp−λkN . Because σ1 = 0, then the variable G does not appear in the second
10
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equation of system (1.2). Therefore, for the dynamics of insulin I(t) we only
need to consider the following subsystem:

dI(t)
dt
= −dI(t), t 6= τn, t 6= λm,
I(λ+m) = I(λm) + σ, t = λm,
I(τ+n ) = I(τn), t = τn,
(2.4)
It is shown in Appendix B that there exists a globally stable Tp periodic
solution with the complete expression (ITp(t), GTp(t)) over the h−th time
interval hTp < t ≤ (h + 1)Tp of system (1.2) for type 1 diabetes. Now we
prove the stability of the positive periodic solution (ITp(t), GTp(t)) for Case
2.
Theorem 2.2 If σ1 = 0, then the positive Tp periodic solution (I
Tp(t), GTp(t))
of system (1.2) for type 1 diabetes is global asymptotically stable.
The Proof is similar to that for Theorem 1, so we omit it here.
Case 3 Insulin injections and glucose infusions are employed with dif-
ferent periods.
Assume λm+1 − λm ≡ TN for all m, and τn+1 − τn ≡ Tp for all n. In this
case, TN is the period of impulsive injections of insulin, Tp is the period of
glucose infusions, m,n(n ∈ N ). Denote ρ = Tp/TN , then ρ either is rational
(i.e. Tp and TN are rational dependent)or is irrational (i.e. Tp and TN are
rational independent). If ρ is rational, then ρ = p/q, p, q ∈ N and p, q are
relatively prime. Let T0 = pTN(= qTp), then system (1.2) is a T0 periodic
system. This means that if ρ is rational, model (1.2 ) can be investigated
by using similar methods as those in Cases 1 and 2; if ρ is irrational, then
the dynamical behavior of model (1.2) becomes more complex and is quite
difficult to investigate theoretically; see more details in reference ([21]).
From the analysis of Case 1 and Case 2 for type 1 diabetes, there is no
insulin produced or secreted from the pancreas and the subcutaneous injec-
tions of insulin can stabilize the glucose-insulin concentration. It is shown
that no matter whether glucose infusions are more frequent than insulin in-
jections or insulin injections are more frequent than glucose infusions, there
exists a positive globally stable periodic solution in system (1.2) for type 1
diabetes, and the periodic solution reflects the periodic oscillations of the
glucose-insulin concentration when glucose infusions and insulin injections
are applied.
11
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When σ1 > 0, then the pancreas of the patients can produce and secrete
a little but not enough insulin. However, it is quite difficult to show the
existence of a periodic solution in this case, so we turn to investigate the
permanence of the system (1.2).
2.2. Permanence of system (1.2) for type 2 diabetes: i.e. σ1 > 0
The main feature of the diagnostics for type 2 diabetes are hyperglycemia
and hyperinsulinemia which are most probably caused by insulin resistance.
In order to compensate for the insulin resistance, pancreatic β-cells need to
secrete more insulin. Therefore, the insulin secretion rate σ1 > 0 in model
(1.2). Now, we investigate the range of variation for glucose concentration
G(t) under impulsive infusions of glucose and insulin concentration I(t) under
impulsive injections of insulin with the open-loop technique for sufficiently
large t > 0. This qualitative result could provide important advances for
developing the artificial pancreas, precluding both hyperglycemia and hypo-
glycemia.
Theorem 2.3 If σ1 > 0, then system (1.2) for type 2 diabetes is perma-
nent.
Proof. From the second equation of system (1.2), we have
−dI(t) ≤
dI(t)
dt
≤ σ1 − dI(t).
When−dI(t) ≤ dI(t)/dt, considering the impulsive effects of Case 1 and Case
2. Then from section 2.1, both subsystems have unique global asymptotically
stable positive periodic solutions, denoted as ITN1 (t) with the period TN and
I
Tp
2 (t) with the period Tp, respectively. We get
ITN1 (t) =


I∗1exp[−d(t− hTN)], t ∈ (hTN , τ1 + hTN ],
I∗1exp[−d∆0]exp[−d(t− τ1 − hTN)],
t ∈ (τ1 + hTN , τ2 + hTN ],
...
I∗1exp[−d
kp−1∑
i=0
∆i]exp[−d(t− τkp − hTN)],
t ∈ (τkp + hTN , (h+ 1)TN ],
12
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where I∗1 = σ/(1− exp[−dTN ]).
I
Tp
2 (t) =


I∗2exp[−d(t− hTp)], t ∈ (hTp, λ1 + hTp],
(I∗2exp(−d∆0) + σ)exp[−d(t− λ1 − hTp)],
t ∈ (λ1 + hTp, λ2 + hTp],
...
{I∗2exp[−d(
kN−1∑
i=1
∆i)] + C}exp[−d(t− λkN − hTp)],
t ∈ (λkN + hTp, (h+ 1)Tp],
where I∗2 = C1/(1− exp[−dTp]).
When dI(t)/dt ≤ σ1 − dI(t), similarly, we can get two global asymptot-
ically stable positive periodic solutions by considering the impulsive effects
of Case 1 and Case 2, denoted as ITN3 (t) and I
Tp
4 (t).
ITN3 (t) =


σ1
d
+ (I∗3 −
σ1
d
)exp[−d(t− hTN)], t ∈ (hTN , τ1 + hTN ],
σ1
d
+ (I∗3 −
σ1
d
)exp(−d∆0)exp[−d(t− τ1 − hTN)],
t ∈ (τ1 + hTN , τ2 + hTN ],
...
σ1
d
+ (I∗3 −
σ1
d
)exp[−d
kp−1∑
i=0
∆i]exp[−d(t− τkp − hTN)],
t ∈ (τkp + hTN , (h+ 1)TN ],
where I∗3 = σ1/d+ σ/(1− exp[−dTN ]),
I
Tp
4 (t) =


σ1
d
+ (I∗4 −
σ1
d
)exp[−d(t− hTp)], t ∈ (hTp, τ1 + hTp],
σ1
d
+ (I∗4 −
σ1
d
)exp(−d∆0)exp[−d(t− τ1 − hTp)],
t ∈ (τ1 + hTp, τ2 + hTp],
...
σ1
d
+ {(I∗4 −
σ1
d
)exp[−d(
kN−1∑
i=1
∆i)] + C}exp[−d(t− λkN − hTp)],
t ∈ (τkN + hTp, (h+ 1)Tp],
where I∗4 = σ1/d+ C1/(1− exp[−dTp]).
Denoted as I˜1(t) = max{I
TN
1 (t), I
Tp
2 ((t)} and I˜2(t) = min{I
TN
3 (t), I
Tp
4 (t)},
then according to the comparison theorem, for any sufficient small ε > 0,
there exists a t0 such that
I˜1(t)− ε < I˜1(t) ≤ I(t) ≤ I˜2(t) < I˜2(t) + ε, t ≥ t0,
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and denoted as
I˜1(T ) = max{I
TN
1 ((h+ 1)TN), I
Tp
2 ((h+ 1)Tp)}
and
I˜2(T ) = min{I
TN
3 (hTN), I
Tp
4 (hTp)},
then we have
I˜1(T ) = lim
t→∞
inf I˜1(t) ≤ lim
t→∞
inf I(t) ≤ lim
t→∞
sup I(t) ≤ I˜2(T ). (2.5)
From equation (2.5) and the second equation of system (1.2), it is easy
to see that
b− (σ2 + ac)G(t)−
akG(t)I˜2(T )
l+I˜2(T )
≤ dG(t)
dt
≤ b− (σ2 + ac)G(t)−
akG(t)I˜1(T )
l+I˜1(T )
,
(2.6)
considering the impulsive effects of Case 1 and Case 2 for equation (2.6). By
the same methods, we can get Gm and GM such that
Gm ≤ lim
t→∞
inf G(t) ≤ lim
t→∞
supG(t) ≤ GM . (2.7)
According to (2.5) and (2.7), the system (1.2) for type 2 diabetes is perma-
nent. This completes the proof.
2.3. Numerical investigations for open-loop control and its biological impli-
cations
In insulin therapies, the use of an insulin pump not only provides the
basic treatment for type 1 diabetes but also provides a feasible alternative
to insulin injections for type 2 diabetes [6-8]. System (1.2) is based on the
open-loop technique with glucose infusions and insulin injections periodically
at different impulsive point series. In this section, we will investigate the
applications of model (1.2) numerically in clinical insulin therapies with the
aim of mimicking the natural pattern of insulin injections by pumps so that
the plasma glucose levels in blood can be controlled at normal levels.
The parameter values presented in Table 2.1 in our simulations are either
determined by previous research [2, 3, 12, 22, 23], or from the models for the
intravenous glucose tolerance test (IVGTT) [24-26]. Besides, the necessary
14
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Table 2.1: Parameter values for the model (1.2) and (1.3)
Parameters Values Units Parameters Values Units
σ1 1.27 µ U/min σ2 5× 10
−6 min−1
a 0.03 mg−1 b 100 mg/min
c 40 mg/min d 0.008 min−1
k 900 mg/min l 80 mg
α1 350 mg
conversions of units are made and the values are adjusted within reasonable
ranges.
For type 1 diabetes, i.e., σ1 = 0, there is no insulin secreted from the pan-
creas. Then an insulin pump is needed for patients to help their cells to take
up glucose. From the analysis of Case 1 and Case 2 in section 2.1, we know
that with different frequencies of glucose infusions and insulin injections, for
the system (1.2) there always exists a globally stable periodic solution for
type 1 diabetes. To substantiate our theoretical results and supply clinical
insulin therapies in the practice, it is reasonable to take 12 hours (i.e., 720
minutes) as a period for insulin injections, and in this period, people always
take up glucose every 4 hours. This is consistent with the character of Case
1, and with other parameters fixed, the numerical results are as shown in
Fig. 2(a) and Fig. 2(b). It is shown that the blood glucose concentrations
and insulin concentrations of the patients change periodically. After three
glucose infusions, we see that the blood glucose level is beyond the reason-
able range (for example, DGL is 125 mg/dl [15]), which can be dangerous
for patients. Therefore, with the help of insulin, the blood glucose level is
maintained within a normal range when glucose infusions are applied at most
twice. That is the reason why doctors advise their patients not to take up
glucose at dinner time. For Case 2, the patients take up glucose every 12
hours and insulin is injected three times in this period (see Fig. 2(c) and
Fig. 2(d)). The stable periodic solution is shown in Fig. 2(c) and Fig. 2(d),
and the results show that the blood glucose level will be always maintained
at a low range, but excessive insulin infusions increase the risk of severe
hypoglycemia [27]. Therefore, to be clinically acceptable, it is not only es-
sential for a model based controller to prevent hyperglycaemia by reducing
the frequencies of glucose infusions, but also to reduce the frequencies of in-
sulin injections to prevent hypoglycemic and hyperinsulinemia episodes by
15
ACCEPTED MANUSCRIPT
A
C
C
E
P
T
E
D
 M
A
N
U
S
C
R
IP
T
making accurate predictions.
For type 2 diabetes, i.e., σ1 > 0, and with all other parameters fixed,
Fig. 3 shows the numerical results for cases when glucose infusions are more
frequent than insulin injections and insulin injections are more frequent than
glucose infusions, respectively. However, it is different from type 1 diabetes
as patients can take up glucose three times without reaching the abnormal
blood glucose level since the pancreases of these patients can secrete a small
amount of insulin. So it presents a direct result of the differences in treatment
between different types of diabetes mellitus.
When a patient injects insulin before he or she takes up glucose, how does
this affects the dynamics of the glucose-insulin system ? To address this, we
assume that a patient injects insulin 15min before he or she takes up glucose
for type 1 diabetes, then we fix all other parameters as shown in Table 2.1
and the simulation result is shown in Fig. 4(a) and Fig. 4(b). Clearly, if the
dose of injected insulin σ is 60µU , then the blood glucose level is beyond the
normal range. When σ = 80µU , then the blood glucose level is within the
normal range. For type 2 diabetes, the blood glucose level is under control
if σ = 60µU (see Fig. 4(c) and Fig. 4(d)), the reason is that the pancreas
can produce and secrete a little insulin. When σ = 80µU , this regime is
more efficient. Thus this regime can control the blood glucose level easily
within a normal range if the dose of injected insulin is chosen appropriately.
In contrast, when a patient injects insulin after he takes up glucose, the
blood glucose level increases immediately and is beyond the normal range
(not shown here), thus insulin injections are not useful.
The numerical results show the periodic solutions which reflect the pe-
riodic oscillations of the glucose concentration and insulin concentration for
the type 1 diabetes and type 2 diabetes, respectively. It is revealed that the
glucose infusion period, the insulin injection period, the dose of impulsive
injection of insulin and the dose of impulsive infusion of glucose play key
roles in affecting the dynamics of the system (1.2).
3. Hybrid impulsive model (1.3) with critical glucose threshold
As mentioned before, insulin injections with the open-loop approach are
widely used in clinical insulin therapies for patients. However, a drawback
of the open-loop control is that this regime changes the life styles of patients
and risks hypoglycemia or hyperinsulinemia. In recent years, with the aims
of improving the life styles of patients, researchers have been making great
16
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efforts in developing an artificial pancreas [9-11], that is, insulin is injected
once the blood glucose level reaches a threshold which is observed by a glucose
monitoring system. Accordingly, the hybrid impulsive model (1.3) meets the
requirements, and it can serve as a prototype to offer reliable predictive
models and efficient control algorithms for designing an artificial pancreas.
In system (1.3), we assume that GC is an adjustable constant threshold
value for glucose level, and
IC =
l(b−GC(σ2 + ac))
GC(σ2 + a(c+ k))− b
which is determined by the intersection of the null-line
−σ2G(t)− a
(
c+
kI(t)
l + I(t)
)
G(t) + b = 0
and the critical glucose thresholdGC . At impulsive point series τn (we assume
that τn − τn−1 = T ), we do not change the life style of patients because
they take up glucose normally. When the blood glucose level reaches CGT,
observed by the glucose monitoring system, then insulin is injected to bring
down the blood glucose level and the DGL can not be reached and exceeded.
In the following, we will investigate the dynamic behaviors of system (1.3)
numerically.
Now, we focus on type 1 diabetes, i.e., σ1 = 0, when there is no insulin
secreted from the pancreas. We fixed parameters as shown in Table 2.1. For
a given CGT (GC = 100mg/dl), when T = 60min, the simulation results
indicate that system (1.3) is free from closed-loop control after two insulin
injections, and the glucose is infused twice at the first small period of insulin
injections and three times at the other (Fig. 5(a) and Fig. 5(b)). It is
revealed that the blood glucose level may exceed 100mg/dl (CGT) at insulin
injection time. However, the blood glucose level will never reach the DGL,
that is, it takes a few minutes for the injected insulin analogues to be absorbed
and start to help the patients to bring down their blood glucose, and that
is why we select CGT as a control parameter rather than DGL. Once the
period T increases to 120min, system (1.3) is free from closed-loop control
after insulin injection, and during the insulin injection period the patients
take up glucose once too, as shown in Fig. 5(c) and Fig. 5(d). Looking back
to Fig. 2(a) and Fig. 2(b), after three glucose infusions, the blood glucose
level is beyond the reasonable range, which can be dangerous for patients,
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and the smaller the period between successive glucose infusions is, the more
dangerous it is for the patient. Compared to Fig. 2(a) and Fig. 2(b), the
results show that the blood glucose level never reaches DGL, which indicates
that the patients will be relieved from hyperinsulinemia and hyperglycaemia.
Meanwhile, if we fix T and other parameters, and change the dose of insulin
within a reasonable range, then the blood glucose concentration is more
easily controlled because the change of insulin leads to the change of the
blood glucose level (Not shown here).
For type 2 diabetes, the parameters are shown in Table 2.1. Also, for a
given CGT (GC = 100mg/dl), we choose Gin as a control parameter because
the change of T can only lead to a slight change in the amplitude compared
with type 1 diabetes (the numerical results is similar to type 1 diabetes).
When Gin = 60mg/dl, the simulation result indicates that the system (1.3)
is free from closed-loop control after insulin injection once, and the glucose
is infused twice during the period of insulin injection (see Fig. 6(a) and
Fig. 6(b)). If we select Gin = 80mg/dl, during the insulin injection period,
the patients take in glucose once (Fig. 5(c) and Fig. 5(d)). When Gin =
100mg/dl, then the insulin is injected once the glucose infusion is applied
because the blood glucose level reaches CGT immediately (Fig. 6(c) and
Fig. 6(d)). Accordingly, when we increase the dose of the glucose infusions,
more frequent injections of insulin are efficient. If we fix other parameters
and choose σ as a controlling parameter, then the results are similar to type
1 diabetes.
Furthermore, we denote the time points at which the blood glucose level
reaches GC as tn(n = 1, 2, · · ·). If mod(tn, T ) ≡ 0, then glucose and insulin
are both injected at the same time tn. If mod(tn, T ) 6= 0, then only insulin
is injected. Besides, denote
∆n = tn − tn−1, (3.1)
with t0 = 0, where n denotes the maximum number at which the G(t) com-
ponent increases and reaches GC within the given time interval and ∆n is
its relatively duration (n may be finite or infinite, which depends on the
solutions of the model (1.3)).
We fix parameters as shown in Table 2.1 and the baseline control param-
eter values are set as Gin = 60mg/dl, σ = 60µU and T = 60min, then the
effect of control parameters on the number n and consequently on the period
∆n can be calculated from the model (1.3) and formula (3.1) numerically
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for a fixed time interval t ∈ [0, 1000] (Fig. 7). The results indicate that the
number n is 10 and the duration ∆n stabilizes after 300min. The effects of
the injection dose of insulin σ on the number n and the period ∆n are shown
in Fig. 7(a). It can be seen that the larger the injection dose of insulin σ is,
the smaller is the number n and consequently the larger is the period ∆n. It
suggests that increasing the dose σ will decrease the number n and postpone
the CGT from being reached. Conversely, the number n is increasing and
the period ∆n is decreasing as the glucose infusion rate Gin increases (Fig.
7(b)). This implies that larger Gin will cause harms to patients. In addition,
it is interesting to see that the duration ∆n switches between 180min and
240min when the glucose infusion rate Gin is set as 80mg/dl. Therefore,
the glucose infusion rate Gin should be chosen carefully to bring down the
blood glucose concentration for a fixed dose σ. Moreover, it is revealed that
the number n and the period ∆n are both increasing as the glucose infusion
period T increases (details see Fig. 7(c)).
These results clarify that model (1.3) proposed here can help us to bring
down the blood glucose level, to protect against hyperinsulinemia and hyper-
glycaemia, to offer reliable predictive models and efficient control algorithms
and to help clinicians to design an artificial pancreas to cure diabetes.
4. Conclusion
Since the pioneering work on the dynamics of plasma insulin concen-
trations that led to the glucose-insulin regulatory system contributing to
insulin therapies [28], numerous of research papers have appeared on the
topic [1, 2, 9, 12, 14, 15, 29]. In recent years, many results have been ob-
tained from the glucose-insulin regulatory system via a mathematical model
of delay differential equations. Recently, Huang et al. proposed two novel
mathematical models with impulsive injections of insulin or its analogues for
type 1 and type 2 diabetes mellitus [12], and they assumed that the constant
glucose infusion rate Gin is described by a continuous process in an impulsive
injection period. However, such models cannot reflect the reality very well
because the constant glucose exogenous infusion is usually a discrete process
[3]. Therefore, we developed a novel glucose-insulin system (1.2) with open-
loop control based on two impulsive point series in order to better reflect the
reality and model the treatment currently available for clinical use. More-
over, in clinical insulin therapies, the most satisfactory treatment would be
one in which glucose infusions could be administered periodically without
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changing the life styles of patients, combined with automatic insulin injec-
tions in a closed-loop technique integrated with a glucose monitoring system.
So we proposed a novel hybrid impulsive model (1.3) with a critical glucose
threshold.
The dynamics of our models were investigated by using the theory of
impulsive differential equations [19, 20]. In particular, the existence and
uniqueness of a positive globally asymptotically stable periodic solution of
system (1.2) for type 1 diabetes was studied analytically, and the permanence
of system (1.2) for type 2 diabetes was shown, which also means that the
glucose concentration level is uniformly bounded above and below. By exten-
sive numerical investigations, we found that when choosing different control
parameters, an attractor from which the concentration of glucose and insulin
oscillates with different amplitudes always exists. The results indicates that
the dynamic behaviors of the glucose-insulin system may be affected dra-
matically by the period, the frequency and the dose of glucose infusions and
insulin injections, and these elements are crucial for insulin therapies.
In practice, a good insulin therapy is one in which the blood glucose level
can be brought down to a normal range (here CGT) without changing the life
style of patients. System (1.3) is proposed based on this ideal. To avoid hy-
perinsulinemia and hyperglycaemia, we assumed that insulin is injected only
when the blood glucose level reaches CGT and periodic repeated intakes of
glucose are applied. The simulation results indicate that the blood glucose
level never reaches or exceeds DGL, the times of insulin injections would
be reduced under certain conditions, and increasing the dose of the glucose
infusions, more frequent injections of insulin are efficient. More importantly,
the factors which affect the number n (i.e. the number at which the blood
glucose reaches GC) and its relatively duration ∆n are discussed. The sim-
ulation results indicate that the number n and duration ∆n largely depends
on the injection dose of insulin, glucose infusion rate Gin and glucose infusion
period T . Therefore, hybrid system (1.3) with closed-loop control is suitable
for providing reliable predictive models and efficient control algorithms for
the development of an artificial pancreas.
Note that two time delays always exist in the normal glucose-insulin reg-
ulatory system: one is the hepatic glucose production delay and the other
is the time delay for insulin-dependent glucose utilization by cells [14]. So
it would be more reasonable for system (1.2) and system (1.3) to take two
delays into account. Furthermore, in this paper, for the sake of simplicity,
the insulin degradation rate is assumed to be proportional to insulin concen-
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tration. However, it is more realistic to assume that the insulin degradation
rate obeys Michaelis-Menten kinetics [15]. Moreover, the effect of physical
exercise on the dynamics of glucose and insulin has been investigated [30],
thus it is interesting to show how does this affects the dynamics if we put this
into our proposed models. Recently, non-smooth dynamic systems or Filip-
pov systems have been applied widely in many fields of science [31-33], as a
result, the dynamical behaviors of the glucose-insulin system could be inves-
tigated more clearly once we consider such models. Consequently, to address
these with the aim of improving strategies for the treatment of diabetes, such
research is planned for the near future and will be reported elsewhere.
Acknowledgements: This work was supported by the Fundamental
Research Funds for the Central Universities (GK201401004), and by the Na-
tional Natural Science Foundation of China (NSFC,11471201, 11171199).
Appendix A. Analyzing system (1.2) for Case 1
Now, we investigate the periodic solution of system (2.1). Since the insulin
dynamics is linear and not affected by the more frequent glucose infusions,
hence the solution of (2.1) is not piecewise-continuous but it is strictly con-
tinuous even at τ1, τ2, · · · , τkp . Therefore, we consider any given time interval
(hTN , (h+1)TN ], where h is a positive integer. Integrating the first equation
of system (2.1) from hTN to (h+ 1)TN yields
I(t) = I(hT+N )exp[−d(t− hTN)], t ∈ (hTN , (h+ 1)TN ].
At time (h+ 1)TN , then insulin is injected once and
I((h+ 1)T+N ) = I(hT
+
N )exp[−dTN ] + σ.
Denote Ih = I(hT
+
N ), then we have the following difference equation:
Ih+1 = exp[−dTN ]Ih + σ,
solving the equation yields a unique steady state:
I∗ =
σ
1− exp[−dTN ]
.
Clearly, exp[−dTN ] < 1, therefore, the system (2.1) has a globally stable TN
periodic solution (denoted by ITN (t)), which can be calculated as follows:
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ITN (t) = I∗exp[−d(t− hTN)], t ∈ (hTN , (h+ 1)TN ]. (A.1)
Substituting ITN (t) into the first equation of (1.2) for I(t), we have

dG(t)
dt
= b− (σ2 + ac)G(t)−
akG(t)ITN (t)
l + ITN (t)
, t 6= τn, t 6= λm,
G(τ+n ) = G(τn) +Gin, t = τn,
G(λ+m) = G(λm), t = λm,
(A.2)
Denote ξ = σ2 + ac, and then integrating the first equation of system (A.2)
from hTN to τ1 + hTN yields
G(t) = G(hT+N )exp[−
∫ t
hT+
N
(ξ + akI
TN (s)
l+ITN (s)
)ds]
+b
∫ t
hT+
N
[exp(−
∫ t
u
(ξ + akI
TN (s)
l+ITN (s)
)ds)]du
= G(hT+N )exp[−ξ(t− hTN)]exp[−ak
∫ t
hT+
N
ITN (s)
l+ITN (s)
ds]
+b
∫ t
hT+
N
{exp[−ξ(t− u)]exp[−ak
∫ t
u
ITN (s)
l+ITN (s)
ds]}du.
(A.3)
From system (2.1), when hT+N ≤ b1 ≤ b2 ≤ (τ1 + hTN), we have
exp[−ak
∫ b2
b1
ITN (t)
l+ITN (t)
dt] = exp[ak
d
∫ b2
b1
−dITN (t)
l+ITN (t)
dt]
= exp[ak
d
∫ b2
b1
(d ln(l+I
TN (t))
dt
)dt]
= exp[ak
d
ln( l+I
TN (b2)
l+ITN (b1)
)]
= ( l+I
TN (b2)
l+ITN (b1)
)
ak
d .
(A.4)
From equation (A.3) and (A.4), when hTN < t ≤ (τ1 + hTN), it follows
G(t) = G(hT+N )exp[−ξ(t− hTN)](
l+ITN (t)
l+ITN (hT+
N
)
)
ak
d
+b
∫ t
hT+
N
{exp[−ξ(t− u)]( l+I
TN (t)
l+ITN (u)
)
ak
d }du
= G(hT+N )exp[−ξ(t− hTN)](
l+ITN (t)
l+ITN (hT+
N
)
)
ak
d
+b(l + ITN (t))
ak
d
∫ t
hT+
N
exp[−ξ(t−u)]
(l+ITN (u))
ak
d
du.
At time τ1 + hTN , glucose infusion is applied once and
G((τ1 + hTN)
+) = G(hT+N )exp(−ξ∆0)(
l+ITN (τ1+hTN )
l+ITN (hT+
N
)
)
ak
d
+b(l + ITN ((τ1 + hTN)
+))
ak
d
∫ (τ1+hTN )+
hT+
N
exp[−ξ(τ1+hTN−u)]
(l+ITN (u))
ak
d
du+Gin.
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Again, integrating the first equation of system (A.2) from τ1+hTN to τ2+hTN
yields
G(t) = G((τ1 + hTN)
+)exp[−ξ(t− τ1 − hTN)](
l+ITN (t)
l+ITN ((τ1+hTN )+)
)
ak
d
+b(l + ITN (t))
ak
d
∫ t
(τ1+hTN )+
exp[−ξ(t−u)]
(l+ITN (u))
ak
d
du
= G(hT+N )exp[−ξ(∆0 + t− τ1 − hTN)](
l+ITN (t)
l+ITN (hT+
N
)
)
ak
d
+b(l + ITN (t))
ak
d {exp[−ξ(t− τ1 − hTN)]
∫ (τ1+hTN )+
hT+
N
exp[−ξ(τ1+hTN−u)]
(l+ITN (u))
ak
d
du
+
∫ t
(τ1+hTN )+
exp[−ξ(t−u)]
(l+ITN (u))
ak
d
du}
+Ginexp[−ξ(t− τ1 − hTN)](
l+ITN (t)
l+ITN ((τ1+hTN )+)
)
ak
d ,
At time τ2 + hTN , glucose is taken up again and it is easy to get G((τ2 +
hTN)
+),
G((τ2 + hTN)
+) = G(hT+N )exp[−ξ(∆0 +∆1)](
l+ITN ((τ2+hTN )
+)
l+ITN (hT+
N
)
)
ak
d
+b(l + ITN ((τ2 + hTN)
+))
ak
d {exp(−ξ∆1)
∫ (τ1+hTN )+
hT+
N
exp[−ξ(τ1+hTN−u)]
(l+ITN (u))
ak
d
du
+
∫ (τ2+hTN )+
(τ1+hTN )+
exp[−ξ(τ2+hTN−u)]
(l+ITN (u))
ak
d
du}+Gin[1 + exp(−ξ∆1)(
l+ITN ((τ2+hTN )
+)
l+ITN ((τ1+hTN )+)
)
ak
d ],
by induction, we can see that
G(t) = G(hT+N )exp[−ξ(
kp−1∑
i=0
∆i)]exp(t− τkp − hTN)(
l+ITN (t)
l+ITN (hT+
N
)
)
ak
d
+b(l + ITN (t))
ak
d A+GinB,
for all t ∈ (τkp + hTN , (h+ 1)TN ], where
A = exp(−ξ
kp−1∑
i=1
∆i)exp(−ξ(t− τkp − hTN))
∫ (τ1+hTN )+
hT+
N
exp[−ξ(τ1+hTN−u)]
(l+ITN (u))
ak
d
du
+exp(−ξ
kp−1∑
i=2
∆i)exp(−ξ(t− τkp − hTN))
∫ (τ2+hTN )+
(τ1+hTN )+
exp[−ξ(τ2+hTN−u)]
(l+ITN (u))
ak
d
du
+ · · ·+
∫ t
(τkp+hTN )
+
exp[−ξ(t−u)]
(l+ITN (u))
ak
d
du,
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and
B = exp(−ξ
kp−1∑
i=1
∆i)exp(−ξ(t− τkp − hTN))(
l+ITN (t)
l+ITN ((τ1+hTN )+)
)
ak
d
+exp(−ξ
kp−1∑
i=2
∆i)exp(−ξ(t− τkp − hTN))(
l+ITN (t)
l+ITN ((τ2+hTN )+)
)
ak
d
+ · · ·+ ( l+I
TN (t)
l+ITN ((τkp+hTN )
+)
)
ak
d .
At time (h+ 1)TN , glucose is not taken up, and we get G((h+ 1)T
+
N ),
G((h+ 1)T+N ) = G(hT
+
N )exp(−ξTN)(
l+ITN ((h+1)T+
N
)
l+ITN (hT+
N
)
)
ak
d
+b(l + ITN ((h+ 1)T+N ))
ak
d A1 +GinB1,
where
A1 = exp(−ξ(TN − τ1))
∫ (τ1+hTN )+
hT+
N
exp[−ξ(τ1+hTN−u)]
(l+ITN (u))
ak
d
du
+exp(−ξ(TN − τ2))
∫ (τ2+hTN )+
(τ1+hTN )+
exp[−ξ(τ2+hTN−u)]
(l+ITN (u))
ak
d
du
+ · · ·+
∫ (h+1)T+
N
(τkp+hTN )
+
exp[−ξ((h+1)TN−u)]
(l+ITN (u))
ak
d
du,
and
B1 = exp(−ξ(TN − τ1))(
l+ITN ((h+1)T+
N
)
l+ITN ((τ1+hTN )+)
)
ak
d
+exp(−ξ(TN − τ2))(
l+ITN ((h+1)T+
N
)
l+ITN ((τ2+hTN )+)
)
ak
d
+ · · ·+ (
l+ITN ((h+1)T+
N
)
l+ITN ((τkp+hTN )
+)
)
ak
d .
Besides it is easy to see ITN (h + 1)T+N = I
TN (hT+N ) = exp[−dTN ]I
∗ + σ ,
Denote Gh = G(hT
+
N ), then we get the following difference equation:
Gh+1 = Ghexp(−ξTN) + b(l + I
TN ((h+ 1)T+N ))
ak
d A1 +GinB1, (A.5)
where
0 < b(l + ITN ((h+ 1)T+N ))
ak
d A1 +GinB1,
0 < exp(−ξTN)
(
l + ITN ((h+ 1)T+N )
l + ITN (hT+N )
)ak
d
= exp(−ξTN) < 1,
then for equation (A.5) there exists a unique positive steady state
G∗ =
b(l + exp[−dTN ]I
∗ + σ)
ak
d A1 +GinB1
1− exp(−ξTN)
,
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consequently, the subsystem (A.2) has a globally stable TN periodic solution
(denote by GTN ), which can be calculated as follows:
GTN (t) =


G1(t), t ∈ (hTN , τ1 + hTN ],
G2(t), t ∈ (τ1 + hTN , τ2 + hTN ],
...
Gkp+1(t), t ∈ (τkp + hTN , (h+ 1)TN ],
(A.6)
where
G1(t) = G
∗exp[−ξ(t− hTN)](
l+ITN (t)
l+ITN (hT+
N
)
)
ak
d
+b(l + ITN (t))
ak
d
∫ t
hT+
N
exp[−ξ(t−u)]
(l+ITN (u))
ak
d
du,
G2(t) = G
∗exp[−ξ(∆0 + t− τ1 − hTN)](
l+ITN (t)
l+ITN (hT+
N
)
)
ak
d
+b(l + ITN (t))
ak
d {exp[−ξ(t− τ1 − hTN)]
∫ (τ1+hTN )+
hT+
N
exp[−ξ(τ1+hTN−u)]
(l+ITN (u))
ak
d
du
+
∫ t
(τ1+hTN )+
exp[−ξ(t−u)]
(l+ITN (u))
ak
d
du}
+Ginexp[−ξ(t− τ1 − hTN)](
l+ITN (t)
l+ITN ((τ1+hTN )+)
)
ak
d ,
and
Gkp+1(t) = G
∗exp[−ξ(
kp−1∑
i=0
∆i)]exp(t− τkp − hTN)(
l+ITN (t)
l+ITN (hT+
N
)
)
ak
d
+b(l + ITN (t))
ak
d A+GinB.
Appendix B. Analyzing system (1.2) for Case 2
Here, we investigate the periodic solution of subsystem (2.4). We con-
sider any given time interval (hTp, (h + 1)Tp], where h is a positive integer.
Integrating the first equation of system (2.4) from hTp to λ1 + hTp yields
I(t) = I(hT+p )exp[−d(t− hTp)], t ∈ (hTp, λ1 + hTp].
At time λ1 + hTp, insulin injection occurs and
I((λ1 + hTp)
+) = I(hT+p )exp(−dλ1) + σ = I(hT
+
p )exp(−d∆0) + σ.
Similarly, integrating the first equation of model (2.4) from λ1 + hTp to
λ2 + hTp yields
I(t) = I((λ1 + hTp)
+)exp[−d(t− λ1 − hTp)]
= (I(hT+p )exp(−d∆0) + σ)exp[−d(t− λ1 − hTp)],
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where t ∈ (λ1+hTp, λ2+hTp]. And at time λ2+hTp, insulin injection occurs
again and
I((λ2 + hTp)
+) = I((λ1 + hTp)
+)exp[−d∆1] + σ
= I(hT+p )exp[−d(∆0 +∆1)] + σexp(−d∆1) + σ,
By induction, we can see that
I(t) = {I(hT+p )exp[−d(
kN−1∑
i=1
∆i)] + C}exp[−d(t− λkN − hTp)],
for all t ∈ (λkN + hTp, (h + 1)Tp], and denote C = σ[exp(−d(
kN−2∑
i=1
∆i) +
exp(−d
kN−2∑
j=2
∆j)+ · · ·+exp(−d∆kN−2)]. At time (h+1)Tp, there is no insulin
injected and
I((h+ 1)T+p ) = I(hT
+
p )exp[−dTp] + σ[exp(−d(
kN−1∑
i=1
∆i)
+exp(−d
kN−1∑
j=2
∆j) + · · ·+ exp(−d∆kN−1)]
= I(hT+p )exp[−dTp] + C1.
Denote Ih = I(hT
+
p ), then we have the following differential equation:
Ih+1 = exp[−dTp]Ih + C1,
solving the equation yields a unique positive steady state:
I∗ =
C1
1− exp[−dTp]
.
Clearly, C1 > 0 and exp[−dTp] < 1 always holds, therefore, system (2.4)
has a globally stable Tp periodic solution (denoted by I
Tp(t)), which can be
calculated as follows:
ITp(t) =


I∗exp[−d(t− hTp)], t ∈ (hTp, λ1 + hTp],
(I∗exp(−d∆0) + σ)exp[−d(t− λ1 − hTp)],
t ∈ (λ1 + hTp, λ2 + hTp],
...
{I∗exp[−d(
kN−1∑
i=1
∆i)] + C}exp[−d(t− λkN − hTp)],
t ∈ (λkN + hTp, (h+ 1)Tp],
(B.1)
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Substituting ITp(t) into the first equation of (1.2) for I(t), we have

dG(t)
dt
= b− (σ2 + ac)G(t)−
akG(t)ITp(t)
l + ITp(t)
, t 6= τn, t 6= λm,
G(λ+m) = G(λm), t = λm,
G(τ+n ) = G(τn) +Gin, t = τn,
(B.2)
then integrating the first equation of (B.2) from hTp to λ1 + hTp yields
G(t) = G(hT+p )exp[−ξ(t− hTp)](
l+ITp (t)
l+ITp (hT+p )
)
ak
d
+b(l + ITp(t))
ak
d
∫ t
hT+p
exp[−ξ(t−u)]
(l+ITp (u))
ak
d
du.
obviously,
G((λ1 + hTp)
+) = G(hT+p )exp(−ξ∆0)(
l+ITp (λ1+hTp)
l+ITp (hT+p )
)
ak
d
+b(l + ITp((λ1 + hTp)
+))
ak
d
∫ (λ1+hTp)+
hT+p
exp[−ξ(λ1+hTp−u)]
(l+ITp (u))
ak
d
du.
Again, integrating the first equation of (B.2) from λ1+hTp to λ2+hTp yields
G(t) = G((λ1 + hTp)
+)exp[−ξ(t− λ1 − hTp)](
l+ITp (t)
l+ITp ((λ1+hTp)+)
)
ak
d
+b(l + ITp(t))
ak
d
∫ t
(λ1+hTp)+
exp[−ξ(t−u)]
(l+ITp (u))
ak
d
du
= G(hT+p )exp[−ξ(∆0 + t− λ1 − hTp)](
l+ITp (t)
l+ITp (hT+p )
)
ak
d
+b(l + ITp(t))
ak
d {exp[−ξ(t− λ1 − hTp)]
∫ (λ1+hTp)+
hT+p
exp[−ξ(λ1+hTp−u)]
(l+ITp (u))
ak
d
du
+
∫ t
(λ1+hTp)+
exp[−ξ(t−u)]
(l+ITp (u))
ak
d
du},
at time λ2 + hTp, it is easy to get G((λ2 + hTp)
+),
G((λ2 + hTp)
+) = G(hT+p )exp[−ξ(∆0 +∆1)](
l+ITp ((λ2+hTp)+)
l+ITp (hT+p )
)
ak
d
+b(l + ITp((λ2 + hTp)
+))
ak
d {exp(−ξ∆1)
∫ (λ1+hTp)+
hT+p
exp[−ξ(λ1+hTp−u)]
(l+ITp (u))
ak
d
du
+
∫ (λ2+hTp)+
(λ1+hTp)+
exp[−ξ(λ2+hTp−u)]
(l+ITp (u))
ak
d
du}.
By induction, we can see that
G(t) = G(hT+p )exp[−ξ(
kN−1∑
i=0
∆i)]exp(t− λkN − hTp)(
l+ITp (t)
l+ITp (hT+p )
)
ak
d
+b(l + ITp(t))
ak
d D,
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for all t ∈ (λkN + hTp, (h+ 1)Tp], where
D = exp(−ξ
kN−1∑
i=1
∆i)exp(−ξ(t− λkN − hTp))
∫ (λ1+hTp)+
hT+p
exp[−ξ(λ1+hTp−u)]
(l+ITp (u))
ak
d
du
+exp(−ξ
kN−1∑
i=2
∆i)exp(−ξ(t− λkN − hTp))
∫ (λ2+hTp)+
(λ1+hTp)+
exp[−ξ(λ2+hTp−u)]
(l+ITp (u))
ak
d
du
+ · · ·+
∫ t
(λkN+hTp)
+
exp[−ξ(t−u)]
(l+ITp (u))
ak
d
du,
At time (h+ 1)Tp, glucose is taken up once, and we get
G((h+ 1)T+p ) = G(hT
+
p )exp(−ξTp)(
l+ITp ((h+1)T+p )
l+ITp (hT+p )
)
ak
d
+b(l + ITp((h+ 1)T+p ))
ak
d D1 +Gin,
where
D1 = exp(−ξ(Tp − λ1))
∫ (λ1+hTp)+
hT+p
exp[−ξ(λ1+hTp−u)]
(l+ITp (u))
ak
d
du
+exp(−ξ(Tp − λ2))
∫ (λ2+hTp)+
(λ1+hTp)+
exp[−ξ(λ2+hTp−u)]
(l+ITp (u))
ak
d
du
+ · · ·+
∫ (h+1)T+p
(λkN+hTp)
+
exp[−ξ((h+1)Tp−u)]
(l+ITp (u))
ak
d
du.
Denote Gh = G(hT
+
p ), then we get the following difference equation:
Gh+1 = Ghexp(−ξTp)(
l+ITp ((h+1)T+p )
l+ITp (hT+p )
)
ak
d
+b(l + ITp((h+ 1)T+p ))
ak
d D1 +Gin,
(B.3)
where
0 < b(l + ITp((h+ 1)T+p ))
ak
d D1 +Gin,
0 < exp(−ξTp)
(
l + ITp((h+ 1)T+p )
l + ITp(hT+p )
)ak
d
< 1.
Then for equation (B.3) there exists a unique steady state
G∗ =
b(l + ITp((h+ 1)T+p ))
ak
d D1 +Gin
1− exp(−ξTp)(
l+ITp ((h+1)T+p )
l+ITp (hT+p )
)
ak
d
,
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consequently, the subsystem (B.2) has a globally stable Tp periodic solution
(denote by GTp), which can be calculated as follows:
GTp(t) =


G11(t), t ∈ (hTp, λ1 + hTp],
G12(t), t ∈ (λ1 + hTp, λ2 + hTp],
...
G1kN+1(t), t ∈ (λkN + hTp, (h+ 1)Tp],
(B.4)
where
G11(t) = G
∗exp[−ξ(t− hTp)](
l+ITp (t)
l+ITp (hT+p )
)
ak
d
+b(l + ITp(t))
ak
d
∫ t
hT+p
exp[−ξ(t−u)]
(l+ITp (u))
ak
d
du,
G12(t) = G
∗exp[−ξ(∆0 + t− λ1 − hTp)](
l+ITp (t)
l+ITp (hT+p )
)
ak
d
+b(l + ITp(t))
ak
d {exp[−ξ(t− λ1 − hTp)]
∫ (λ1+hTp)+
hT+p
exp[−ξ(λ1+hTp−u)]
(l+ITp (u))
ak
d
du
+
∫ t
(λ1+hTp)+
exp[−ξ(t−u)]
(l+ITp (u))
ak
d
du}
and
G1kN+1(t) = G
∗exp[−ξ(
kN−1∑
i=0
∆i)]exp(t− λkN − hTp)(
l+ITp (t)
l+ITp (hT+p )
)
ak
d
+b(l + ITp(t))
ak
d D.
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Figure Legends
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Figure 1: Dangerous glucose level (DGL)=lowest blood level that will cause harm to
patients. Critical glucose threshold (CGT)= blood glucose level at which insulin should be
injected to prevent an increasing blood glucose concentration from reaching the dangerous
glucose level for patients. The arrows indicate points when the blood glucose levels exceed
the critical glucose threshold and an insulin therapy method would be applied.
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Figure 2: Numerical results for type 1 diabetes of system (1.2). (a) and (b) for Case 1
with σ = 60µU , Gin = 100mg, kp = 3, TN = 720min, G0 = 100mg/dl, I0 = 50µU/ml and
∆i = ∆. (a) Glucose profile with three glucose infusions within an insulin injection period,
(b) Insulin profile with three glucose infusions within an insulin injection period. (c) and
(d) for Case 2 with σ = 60µU , Gin = 100mg, kN = 3, Tp = 720min, G0 = 100mg/dl,
I0 = 50µU/ml and ∆i = ∆. (c) Glucose profile with three insulin injections within an
glucose infusion period, (d) Insulin profile with three insulin injections within a glucose
infusion period.
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Figure 3: Numerical results for type 2 diabetes of system (1.2). (a) and (b) for Case 1
with σ = 60µU , Gin = 100mg, kp = 3, Tp = 720min, G0 = 100mg/dl, I0 = 50µU/ml and
∆i = ∆. (a) Glucose profile with three glucose infusions within an insulin injection period,
(b) Insulin profile with three insulin injections within a glucose infusion period. (c) and
(d) for Case 2 with σ = 60µU , Gin = 100mg, kN = 3, Tp = 720min, G0 = 100mg/dl,
I0 = 50µU/ml and ∆i = ∆. (c) Glucose profile with three insulin injections within a
glucose infusion period, (d) Insulin profile with three insulin injections within a glucose
infusion period.
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Figure 4: Numerical results of system (1.2). (a) and (b) for type 1 diabetes with Gin =
100mg, TN = 165min, Tp = 180min, G0 = 100mg/dl, I0 = 50µU/ml, and ∆i = ∆. (a)
Glucose profile with insulin injections 15min before uptakes of glucose, (b) Insulin profile
with insulin injections 15min before uptakes of glucose. (c) and (d) for type 2 diabetes
with Gin = 100mg, TN = 165min, Tp = 180min, G0 = 100mg/dl, I0 = 50µU/ml and
∆i = ∆. (a) Glucose profile with insulin injections 15min before uptakes of glucose, (b)
Insulin profile with insulin injections 15min before uptakes of glucose.
36
ACCEPTED MANUSCRIPT
A
C
C
E
P
T
E
D
 M
A
N
U
S
C
R
IP
T
0 500 1000 1500 2000
0
50
100
150
t(min)
G
lu
co
se
(m
g/d
l)
(a)
0 500 1000 1500 2000
0
20
40
60
80
t(min)
In
su
lin
(µ/
m
l)
(b)
0 500 1000 1500 2000
0
50
100
150
200
t(min)
G
lu
co
se
(m
g/d
l)
(c)
0 500 1000 1500 2000
0
20
40
60
80
t(min)
In
su
lin
()µ
/m
l)
(d)
Figure 5: Numerical results for type 1 diabetes of system (1.3) with σ = 60µU , Gin =
80mg, GC = 100mg/dl, G0 = 100mg/dl, I0 = 50µU/ml, T = 60min for (a) and (b),
T = 120min for (c) and (d). (a) and (c) Glucose profile with insulin therapy, (b) and (d)
Insulin profile with insulin therapy.
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Figure 6: Numerical results for type 2 diabetes of system (1.3) with σ = 60µU , T =
120min, GC = 100mg/dl, G0 = 100mg/dl, I0 = 50µU/ml , Gin = 60mg for (a) and (b),
Gin = 100mg for (c) and (d). (a) and (c) Glucose profile with insulin therapy, (b) and (d)
Insulin profile with insulin therapy.
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Figure 7: The effects of control parameters σ, Gin and T on the number of n and period
∆n for type 2 diabetes of system (1.3). The baseline parameter values are as follows:
σ = 60µU , T = 60min, GC = 60mg/dl, G0 = 100mg/dl, I0 = 50µU/ml, other parameters
are fixed in Table 2.1. Here we run the model (1.3) from 0 to 1000 and plot the effects of
the injection dose of insulin σ on the number of n and period ∆n in (a), glucose infusion
rate Gin in (b) and glucose infusion period T in (c).
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